PMID- 21267385
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20110714
LR  - 20211020
IS  - 1738-5555 (Electronic)
IS  - 1738-5520 (Print)
IS  - 1738-5520 (Linking)
VI  - 40
IP  - 12
DP  - 2010 Dec
TI  - Effect of Lacidipine on Blood Pressure and Endothelial Function in 
      Mild-to-Moderate Essential Hypertension Patients With Diabetes in Korea.
PG  - 632-8
LID - 10.4070/kcj.2010.40.12.632 [doi]
AB  - BACKGROUND AND OBJECTIVES: The aim of this study was to evaluate the efficacy of 
      lacidipine in reducing blood pressure (BP) and to determine its effect on 
      endothelial function in mild-to-moderate hypertensive patients with type 2 
      diabetes mellitus (DM). SUBJECTS AND METHODS: This was a prospective, 
      multicenter, open-label, single-arm study, enrolling 290 patients with 
      mild-to-moderate hypertension and type 2 DM. Patients were initially treated with 
      2 mg lacidipine orally once daily for 4 weeks, which was then increased as 
      necessary every 4 weeks to a maximal dose of 6 mg daily. The primary endpoint was 
      the mean change in systolic blood pressure (SBP) from baseline after 12 weeks of 
      treatment. Secondary endpoints included mean changes in diastolic blood pressure 
      (DBP), flow-mediated vasodilatation (FMD), and serum concentrations of 
      biochemical markers such as high-sensitivity C-reactive protein (hs-CRP), 
      monocyte chemo-attractant protein-1 (MCP-1), matrix metalloproteinase-9 (MMP-9), 
      and plasminogen activator inhibitor-1 (PAI-1). RESULTS: Lacidipine treatment 
      significantly reduced SBP by -13.4+/-13.0 mmHg (p<0.001) and DBP by -6.2+/-9.3 mmHg 
      (p<0.001). Lacidipine treatment did not improve endothelial-dependent 
      vasodilatation, despite significantly improved nitroglycerin-induced, 
      endothelial-independent vasodilatation. MCP-1 levels significantly decreased from 
      283.66+/-110.08 pg/mL to 257.83+/-100.23 pg/mL (p<0.001); whereas there were no 
      significant changes in the levels of hs-CRP, MMP-9, or PAI-1. CONCLUSION: Twelve 
      weeks of treatment with lacidipine was effective and well tolerated in 
      mild-to-moderate hypertensive patients with type 2 DM. In spite of inducing a 
      significant reduction in MCP-1 levels, lacidipine did not improve endothelial 
      function.
FAU - Kim, Dae-Hee
AU  - Kim DH
AD  - Department of Internal Medicine, College of Medicine, Seoul National University, 
      Seoul, Korea.
FAU - Oh, Il-Young
AU  - Oh IY
FAU - Lee, Hae-Young
AU  - Lee HY
FAU - Kim, Yong-Jin
AU  - Kim YJ
FAU - Kim, Hyo-Soo
AU  - Kim HS
FAU - Kim, Cheol-Ho
AU  - Kim CH
FAU - Oh, Byung-Hee
AU  - Oh BH
FAU - Kim, Kwon-Sam
AU  - Kim KS
FAU - Kim, Doo-Il
AU  - Kim DI
FAU - Kim, Young-Dae
AU  - Kim YD
FAU - Ryu, Kyu-Hyung
AU  - Ryu KH
FAU - Park, Si-Hoon
AU  - Park SH
FAU - Baek, Sang-Hong
AU  - Baek SH
FAU - Shin, Dong-Gu
AU  - Shin DG
FAU - Shim, Wan Joo
AU  - Shim WJ
FAU - Ahn, Tae-Hoon
AU  - Ahn TH
FAU - Oh, Seok-Kyu
AU  - Oh SK
FAU - Lee, Seung-Hwan
AU  - Lee SH
FAU - Lee, Sung-Yun
AU  - Lee SY
FAU - Jeong, Myung-Ho
AU  - Jeong MH
FAU - Chung, Wook-Sung
AU  - Chung WS
FAU - Jeong, Jun-Young
AU  - Jeong JY
FAU - Choi, So-Yeon
AU  - Choi SY
FAU - Choi, Si-Wan
AU  - Choi SW
FAU - Hyon, Min-Su
AU  - Hyon MS
LA  - eng
PT  - Journal Article
DEP - 20101231
PL  - Korea (South)
TA  - Korean Circ J
JT  - Korean circulation journal
JID - 101247141
PMC - PMC3025336
OTO - NOTNLM
OT  - Diabetes mellitus
OT  - Endothelium
OT  - Hypertension
OT  - Lacidipine
EDAT- 2011/01/27 06:00
MHDA- 2011/01/27 06:01
PMCR- 2010/12/01
CRDT- 2011/01/27 06:00
PHST- 2010/03/03 00:00 [received]
PHST- 2010/05/27 00:00 [accepted]
PHST- 2011/01/27 06:00 [entrez]
PHST- 2011/01/27 06:00 [pubmed]
PHST- 2011/01/27 06:01 [medline]
PHST- 2010/12/01 00:00 [pmc-release]
AID - 10.4070/kcj.2010.40.12.632 [doi]
PST - ppublish
SO  - Korean Circ J. 2010 Dec;40(12):632-8. doi: 10.4070/kcj.2010.40.12.632. Epub 2010 
      Dec 31.